It’s only fair to share… Funapide TV 45070, XEN-402, Funapide, (+)- фунапид فونابيد 呋纳匹特 Molecular FormulaC22H14F3NO5 Average mass429.345 Da (S)-1′-[(5-Methyl-2-furyl)methyl]spiro[6H-furo[3,2-f][1,3]benzodioxole-7,3′-indoline]-2′-one Spiro(furo(2,3-F)-1,3-benzodioxole-7(6H),3′-(3H)indol)-2′(1’H)-one, 1′-((5-(trifluoromethyl)-2-furanyl)methyl)-, (3’S)- (3’S)-1′-((5-(Trifluoromethyl)furan-2-yl)methyl)-2H,6H-spiro(furo(2,3-F)(1,3)benzodioxole-7,3′-indol)-2′(1’H)-one Spiro[furo[2,3-f]-1,3-benzodioxole-7(6H),3′-[3H]indol]-2′(1’H)-one, 1′-[[5-(trifluoromethyl)-2-furanyl]methyl]-, (7S)- TV-45070 UNII-A5595LHJ2L XEN-401-S XEN402 (3’S)-1′-{[5-(trifluoromethyl)furan-2-yl]methyl}-2H-6H-spiro[furo[2,3-f]-1,3-benzodioxole-7,3′-indol]-2′(1’H)-one (7S)-1′-{[5-(Trifluoromethyl)-2-furyl]methyl}spiro[furo[2,3-f][1,3]benzodioxole-7,3′-indol]-2′(1’H)-one 1259933-16-8 CAS UNII-A5595LHJ2L Phase II clinical trials for Postherpetic neuralgia (PHN) Treatment of Neuropathic Pain Originator Xenon Pharmaceuticals Developer Teva Pharmaceutical Industries; Xenon Pharmaceuticals Class Benzodioxoles; Fluorobenzenes; …
Tag «PHASE 2»
Prexasertib , прексасертиб , بريكساسيرتيب , 普瑞色替 ,
It’s only fair to share… Prexasertib Captisol® enabled prexasertib; CHK1 Inhibitor II; LY 2606368; LY2606368 MsOH H2O 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile 2-Pyrazinecarbonitrile, 5-[[5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino]- Name Prexasertib Lab Codes LY-2606368 Chemical Name 5-({5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl}amino)pyrazine-2-carbonitrile Chemical Structure Molecular Formula C18H19N7O2 UNII UNII:820NH671E6 Cas Registry Number 1234015-52-1 OTHER NAMES прексасертиб [Russian] [INN] بريكساسيرتيب [Arabic] [INN] 普瑞色替 [Chinese] [INN] Originator Array BioPharma Developer Eli Lilly, National Cancer Institute Mechanism Of Action …
GSK 2330672
It’s only fair to share… GSK 2330672 GSK 672; GSK-2330672 RN: 1345982-69-5 UNII: 386012Z45S CAS: 1345982-69-5 Chemical Formula: C28H38N2O7S Molecular Weight: 546.68 Pentanedioic acid, 3-((((3R,5R)-3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-methoxy-1,1-dioxido-5-phenyl-1,4-benzothiazepin-8-yl)methyl)amino)- Pentanedioic acid, 3-((((3R,5R)-3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-methoxy-1,1-dioxido-5-phenyl-1,4-benzothiazepin-8-yl)methyl)amino)- 3-({[(3R,5R)-3-butyl-3-ethyl-7-(methyloxy)-1 ,1 -dioxido-5-phenyl- 2,3,4,5-tetrahydro-1 ,4-benzothiazepin-8-yl]methyl}amino)pentanedioic acid 3-[[[(3R,5R)-3-Butyl-3-ethyl-2,3,4,5-tetrahydro-7-methoxy-1,1-dioxido-5-phenyl-1,4-benzothiazepin-8-yl]methyl]amino]pentanedioic acid Originator GlaxoSmithKline Class Antihyperglycaemics Mechanism of Action Sodium-bile acid cotransporter-inhibitors Highest Development Phases Phase II Primary biliary cirrhosis; Pruritus; Type 2 diabetes mellitus Phase …
GSK 2982772
It’s only fair to share… CAS: 1622848-92-3 (free base), 1987858-31-0 (hydrate) Chemical Formula: C20H19N5O3 Molecular Weight: 377.404 5-Benzyl-N-[(3S)-5-methyl-4-oxo-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]-4H-1,2,4-triazole-3-carboxamide (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][l,4]oxazepin-3-yl)-4H-l,2,4- triazole-3-carboxamide 3-(Phenylmethyl)-N-[(3S)-2,3,4,5-tetrahydro-5-methyl-4-oxo-1,5-benzoxazepin-3-yl]-1H-1,2,4-triazole-5-carboxamide (S)-5-Benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide GSK2982772 is a potent and selective receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate for the Treatment of Inflammatory Diseases. GSK2982772 is, currently in phase 2a clinical studies for psoriasis, rheumatoid arthritis, and …
Debio-1452
It’s only fair to share… Debio-1452, AFN 1252 AFN-1252; UNII-T3O718IKKM; API-1252; CAS 620175-39-5; CHEMBL1652621; (E)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide MFC22 H21 N3 O3 2-Propenamide, N-methyl-N-[(3-methyl-2-benzofuranyl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- MW375.42 Phase 2, clinical trials for the oral treatment of staphylococcal infections, including hospital and community-acquired MRSA and acute bacterial skin and skin structure infections Qualified Infectious Disease Product designation GlaxoSmithKline plc INNOVATOR Debiopharm …
Tradipitant, традипитант , تراديبيتانت , 曲地匹坦 ,
It’s only fair to share… Tradipitant VLY-686, LY686017 традипитант تراديبيتانت [Arabic] 曲地匹坦 [Chinese] Molecular Formula C28H16ClF6N5O Average mass 587.903 Da 622370-35-8 CAS Methanone, [2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-(4-pyridinyl)-1H-1,2,3-triazol-4-yl]-3-pyridinyl](2-chlorophenyl)- (2-(1-(3,5-bis(trifluoromethyl)benzyl)-5-(pyridin-4-yl)-1H-1,2,3-triazol-4-yl)pyridin-3-yl)(2-chlorophenyl)methanone [2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-(4-pyridinyl)-1H-1,2,3-triazol-4-yl]-3-pyridinyl](2-chlorophenyl)methanone PHASE 2, Gastroparesis; Pruritus pyridine-containing NK-1 receptor antagonist ie tradipitant, useful for treating anxiety, pruritus and alcoholism. Vanda Pharmaceuticals, under license from Eli Lilly, was developing tradipitant, a NK1 antagonist, for treating anxiety …
AZD 8931, Sapitinib,
It’s only fair to share… AZD 8931, Sapitinib, SAPATINIB PHASE 2, at AstraZeneca for the treatment of non-small cell lung cancer. CAS 848942-61-0, MF C23H25ClFN5O3, MW 473.9, pan-EGFR/pan-erbB inhibitor 4-[[4-[(3-Chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-methyl-1-piperidineacetamide 4-(3-Chloro-2-fluoroanilino)-7-methoxy-6-[[1-(N-methylcarbamoylmethyl)piperidin-4-yl] oxy]quinazoline 4-(3-Chloro-2-fluoroanilino)-7-methoxy-6-[[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy]quinazoline 2-[4-[4-(3-Chloro-2-fluoro-anilino)-7-methoxy-quinazolin-6-yl]oxy-1-piperidyl]-N-methyl-acetamide AZD8931 is an oral, equipotent inhibitor of ErbB1, ErbB2 and ErbB3 receptor signaling. WO 2005028469 Inventors Robert Hugh Bradbury, Laurent Francois Andre Hennequin, …
Lorlatinib, лорлатиниб , لورلاتينيب , 洛拉替尼 , PF-6463922
It’s only fair to share… Lorlatinib, PF-6463922 For Cancer; Non-small-cell lung cancer Molecular Formula C21H19FN6O2 Average mass 406.413 Da Phase 2 WO 2013132376 Andrew James Jensen, Suman Luthra, Paul Francis RICHARDSON Applicant Pfizer Inc. (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-4,8- methenopyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile (16R)-19-Amino-13-fluoro-4,8,16-trimethyl-9-oxo-17-oxa-4,5,8,20-tetraazatetracyclo[16.3.1.02,6.010,15]docosa-1(22),2,5,10,12,14,18,20-octaene-3-carbonitrile (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile CAS 1454846-35-5 [RN] UNII:OSP71S83EU лорлатиниб [Russian] لورلاتينيب [Arabic] 洛拉替尼 [Chinese] Ros1 tyrosine kinase receptor inhibitor; Anaplastic lymphoma kinase receptor inhibitor useful …
MK 0633, SETILEUTON
It’s only fair to share… MK 0633, SETILEUTON (-)-enantiomer 910656-27-8 CAS free form MW 463.3817, C22 H17 F4 N3 O4 FREE FORM Tosylate cas 1137737-87-1 2H-1-Benzopyran-2-one, 4-(4-fluorophenyl)-7-[[[5-[(1S)-1-hydroxy-1-(trifluoromethyl)propyl]-1,3,4-oxadiazol-2-yl]amino]methyl]- 4-(4-Fluorophenyl)-7-[[[5-[(1S)-1-hydroxy-1-(trifluoromethyl)propyl]-1,3,4-oxadiazol-2-yl]amino]methyl]-2H-1-benzopyran-2-one WO2006099735A1 Inventors Thiadiazole substituted coumarin derivatives and their use as leukotriene biosynthesis inhibitor WO 2006099735 A1Marc Blouin, Erich L. Grimm, Yves Gareau, Marc Gagnon, Helene Juteau, Sebastien Laliberte, Bruce …
Brigatinib, Бригатиниб, بريغاتينيب , 布格替尼 ,
It’s only fair to share… Brigatinib, AP26113 Molecular Formula: C29H39ClN7O2P Molecular Weight: 584.102 g/mol CAS 1197953-54-0 2,4-Pyrimidinediamine, 5-chloro-N4-[2-(dimethylphosphinyl)phenyl]-N2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]- Бригатиниб[Russian][INN] بريغاتينيب[Arabic][INN] 布格替尼[Chinese][INN] 5-chloro-N4-[2-(dimethylphosphinyl)phenyl]-N2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-2,4-pyrimidinediamine AP-26113 MFCD29472221 UNII:HYW8DB273J In 2016, orphan drug designation was assigned to the compound in the U.S. for the treatment of ALK, ROS1 or EGFR-positive non-small cell lung cancer (NSCLC). WO 2009143389 PDT PAT Inventors Yihan …